# BPC-157 vs TB-500: Different Molecules, Different Mechanisms, Different Studies > Two repair compounds that share a shelf but not a pathway. Their mechanisms, evidence bases, molarity arithmetic and certificate checks compared — and which suits your model. Web page: https://peptidemedixeu.com/en/learn/bpc-157-vs-tb-500/ · Peptide Medix EU · 8 min read · Updated: 2025-11-06 Laboratories ask about these two more than any other repair-associated research compounds, yet they are in no way variants of one another. One is a fifteen-residue pentadecapeptide traced to gastric juice, whose reported activity revolves around vessel formation and growth-factor pathways. The other is a seven-residue [N-acetylated fragment](https://peptidemedixeu.com/en/glossary/acetylation/) derived from thymosin beta-4, organised around a motif that binds actin. Different parents, different chain lengths, different proposed pathways, and molecular weights that differ roughly fourfold. When deciding between [BPC-157 and](https://peptidemedixeu.com/en/products/bpc-157/) the thymosin fragment, what settles it is whether your model reads out vessels and growth factors or cytoskeleton and cell movement. Each arrives as lyophilized powder accompanied by a lot-matched HPLC certificate. Vial options run 5, 10, 15 and 20 mg for the pentadecapeptide and 5, 10 and 20 mg for [TB-500](https://peptidemedixeu.com/en/products/tb-500/), and you will find them together in tissue repair and healing peptides. Neither is for human use: they are laboratory reference chemicals intended for cell and preclinical study. ## Two unrelated molecules that share a shelf Their pairing owes more to how the market organises its shelves than to anything in biology. The pentadecapeptide traces back to gastroenterology, where body protection compound was described as a cytoprotective protein present in gastric secretions; the research peptide reproduces one stretch of that larger sequence. TB-500's roots lie in cell biology of the cytoskeleton, thymosin beta-4 being the dominant sequesterer of actin monomers across many cell types, with the fragment carving out the region usually held responsible. What draws the two together is that their respective literatures report overlapping outcomes — closure of wounds, formation of granulation tissue, ingrowth of vessels, recovered tensile strength in connective tissue. Overlapping outcomes are not a shared pathway, however, and appreciating that distinction is exactly what makes it sensible to run them in one study and unwise to treat either as a stand-in for the other. ## Reported mechanisms, with due caution ### BPC-157 Nothing in the published record identifies a receptor for this peptide, and the omission is substantive rather than trivial. Rodent papers propose a scattering of routes: enhanced signalling via growth-factor receptors, VEGFR2 above all; involvement of nitric oxide signalling; changes in vessel formation; and altered focal-adhesion and paxillin signalling in cultured cells. Essentially all of it derives from animals and cell systems, and a modest number of laboratories account for much of the output, so replication by outside groups lags behind the raw paper count. Anyone adopting the compound should therefore treat its mechanism as something still to be established, not as settled background. ### TB-500 Here the proposal is tighter but also more limited in scope. Thymosin beta-4 binds G-actin monomers and thereby governs the supply available for filament assembly, and residues 17 through 23 hold the relevant motif. A fragment carrying that motif would be expected to alter actin turnover and, by extension, how cells move — which matches its predominance in migration and wound-closure assays. But seven residues are not forty-three, and results [described for the complete thymosin beta-4](https://peptidemedixeu.com/en/products/thymosin-beta-4-full/) protein cannot be assumed to apply. Where the entire protein is what a study needs, order full-length thymosin beta-4; our background piece on the fragment sets out why the two are not equivalent. ## The shape of each evidence base Form differs as much as substance. Work on the pentadecapeptide leans heavily on intact animals: tendon and muscle subjected to transection or crush and then assessed by histology and tensile testing, induced lesions in the digestive tract, and a smaller number of vascular and neurological preparations. Culture experiments exist but play a supporting role, and because so much is done [in whole animals](https://peptidemedixeu.com/en/glossary/in-vivo/), published readouts often describe tissues rather than molecular pathways. The thymosin fragment and its parent protein turn up far more often in tightly defined cell systems: scratch-wound and transwell assays, endothelial tube formation, models of corneal and dermal repair — settings where the actin hypothesis can be interrogated head-on. Cardiac studies using the intact protein form a distinct subgroup, whose findings should never be read across to the seven-residue fragment. For a group weighing one against the other, this structural difference in the evidence often counts for as much as mechanism does: a laboratory with a working migration assay will reach an interpretable answer with the fragment considerably faster than with the pentadecapeptide, whose best evidence sits in animal experiments requiring far more time. ## Matching the compound to the research question ### Pick BPC-157 for vascular, gastrointestinal and connective-tissue models For endpoints such as new vessel ingrowth, integrity of the intestinal mucosa, or the tensile behaviour of tendon and ligament, this peptide comes with far more published material to compare against. Its resistance to acid also leaves it the only one of the pair with a serious oral and intragastric research record — [the capsule format](https://peptidemedixeu.com/en/products/bpc-157-capsules/) versus vials page explains how presentation reshapes a study. ### Pick TB-500 for migration and cytoskeletal readouts Where the experiment is a scratch-wound, transwell or live-imaging migration assay, or where actin organisation is the endpoint, the thymosin fragment maps to a specific molecular interaction and is by far the easier probe to interpret mechanistically. Its very small mass is a bonus too: one milligram supplies a generous molar quantity, which helps when plate work calls for many wells. ### Use both when additivity is the question Given that the two proposed pathways are unconnected, running them together is a defensible way to ask whether two repair-associated inputs add up or merely overlap at a common endpoint. That reasoning is precisely what the co-formulated vial containing both is built on, and it saves one reconstitution and the pipetting error attached to it. What such an arm cannot do is show which compound did what; assigning credit demands single-compound arms in parallel. ## Differences in handling, reconstitution and storage Each is a short, strongly polar sequence that takes up aqueous diluent without difficulty, and neither foams or sticks to surfaces the way lipidated molecules do. Keep sealed vials frozen; let them warm fully before the septum is pierced, so that cold powder does not attract condensation; and introduce diluent along the inside wall of the vial instead of straight onto the cake. Two contrasts matter. Given its length, the pentadecapeptide copes remarkably well with acidic aqueous conditions — a legacy of where it was found — which makes it the more forgiving choice across varied buffer pH. The thymosin fragment, being so light, magnifies any error made by weight: one milligram at 889.02 g/mol supplies about 1.125 micromoles, while one milligram of the pentadecapeptide at 1419.55 g/mol supplies about 0.704 micromoles. Prepare both at the same mg/mL and the molar concentrations diverge by around sixty percent, so any head-to-head experiment has to be matched on moles. Treat the following as bench arithmetic and nothing more: adding 2 mL of diluent to a 5 mg vial produces 2.5 mg/mL, that is 2,500 mcg/mL, so 250 mcg sits in every 0.1 mL. Split both into single-use portions so nothing is thawed and refrozen — our reconstitution guide and storage guide go further. ## Purity, identity and certificate checks Insist on the certificate tied to the lot in your hand, and check three things: a purity figure supported by a chromatogram you can actually see, a mass result consistent with the theoretical weight (1419.55 g/mol for the pentadecapeptide, 889.02 g/mol for the thymosin fragment), and a lot number that matches the label. Beyond that, each sequence invites one particular check. A Pro-Pro-Pro stretch runs through the pentadecapeptide, and proline-rich regions readily generate truncation and deletion by-products during assembly — these surface as neighbouring peaks rather than conspicuous contaminants. For the fragment, the acetyl group on its N-terminus is the defining feature; lose it and the mass drops by 42 Da, producing something that is no longer the molecule any actin-binding argument refers to, so acetylation has to be demonstrated rather than presumed. What a complete certificate ought to contain is set out in our COA guide. ## Regulatory position Both compounds ship as laboratory chemicals and are not for human consumption. Neither has been authorised as a medicine in the EU or the United States, neither qualifies as a food supplement, and in both cases the published evidence is preclinical throughout — rodents and cultured cells. Our [overview of recovery research](https://peptidemedixeu.com/en/learn/peptides-for-healing-and-recovery-research-overview/) gives wider context on this family of tools. ## Frequently asked questions ### How do BPC-157 and TB-500 principally differ? Their origins and their proposed pathways. One is a fifteen-residue stretch of a cytoprotective protein found in gastric secretions, associated with vessel formation and growth-factor signalling. The other is seven residues taken from thymosin beta-4, acetylated at the N-terminus, and tied to actin turnover and cell movement. Chemically they have nothing in common. ### Is a receptor known for either compound? For the pentadecapeptide, no receptor appears anywhere in the published record — a real weakness in its mechanistic story. The thymosin fragment is thought to act by binding actin monomers directly, so no cell-surface receptor is invoked. Neither behaves like a conventional agonist. ### Is TB-500 identical to thymosin beta-4? It is not. The parent protein runs to forty-three residues, whereas the fragment covers only residues 17 to 23 and adds an acetyl group at the N-terminus. It captures the actin-binding motif but is not the protein, so data generated with the intact molecule do not carry over automatically. ### Can both be prepared at the same milligram concentration for comparison? Not if the comparison is meant to hold up. Weighing out a milligram gives roughly 1.125 micromoles of the 889.02 g/mol fragment against roughly 0.704 micromoles of the 1419.55 g/mol pentadecapeptide — about sixty percent more material in molar terms. Comparative work must be set up and reported on a molar basis. ### Why are the two so often supplied in a single vial? Because the pathways proposed for them do not overlap, which makes the pair a sensible probe of whether two repair-related inputs combine additively at one endpoint. Combining them also removes a reconstitution step. The drawback is attribution: to say which compound produced what, you need separate single-compound arms. ### What should be checked on each compound's certificate of analysis? With the pentadecapeptide, examine peaks sitting close to the main one, because its triple-proline run encourages truncation and deletion by-products during synthesis. With the fragment, get explicit confirmation of N-terminal acetylation: without it the mass falls by 42 Da and the material no longer supports any actin-binding interpretation. ### How robust is the evidence for these two compounds? It stops at the preclinical stage. Cultured cells and rodent experiments make up almost all of both literatures, and for the pentadecapeptide a disproportionate share comes from a handful of groups, leaving less outside replication than the number of papers might imply. Both are sold purely as laboratory reference chemicals. ## Related products - [BPC-157](https://peptidemedixeu.com/en/products/bpc-157/): from €34 --- For laboratory research use only. This page is provided for scientific and educational information. Materials referenced here are sold strictly for in-vitro laboratory research by qualified professionals — not for human or veterinary use, and nothing on this page is medical advice.